Trial Profile
Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids (Omacor) for the Treatment of IgA Nephropathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications IgA nephropathy
- Focus Registrational; Therapeutic Use
- Sponsors Kuhnil Pharmaceutical Company
- 05 Apr 2014 New trial record
- 26 Sep 2012
- 21 Oct 2008